RVMD Chief Executive Maintains Strong Position Despite Planned Stock Sale

Q: How many RVMD shares does Mark Goldsmith own after the June 2025 transaction?

After the transaction, Mark Goldsmith beneficially owns: 428,720 shares directly (including 218,188 RSUs and 652 ESPP shares), plus indirect ownership through trusts of: 20,424 shares in the Jonathan Goldsmith Revocable Trust, 20,424 shares in the Rebecca Eve Goldsmith Trust, and 465,604 shares in the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Revolution Medicines (RVMD) President and CEO Mark A. Goldsmith reported insider trading activity on June 16, 2025. The executive sold 13,496 shares at a weighted average price of $39.83 per share as part of a pre-planned Rule 10b5-1 trading plan established on May 31, 2023. The sale was executed to satisfy tax withholding obligations related to vesting restricted stock units (RSUs).

Following the transaction, Goldsmith's holdings include:

Direct ownership: 428,720 shares (including 218,188 RSUs and 652 shares from ESPP)
Indirect ownership: 506,452 shares total through three trusts: - 465,604 shares in family revocable living trust - 20,424 shares each in two additional trusts

The transaction was executed through multiple trades ranging from $39.60 to $39.83 per share, with the executive maintaining significant equity stake in the company through both direct and indirect holdings.

Insider Trade Summary

Net Seller: 13,496 shares ($537,546)

Net Sell 4 txns

Insider GOLDSMITH MARK A

Role See Remarks

Sold 13,496 shs ($538K)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,496	$39.83	$538K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 428,720 shares (Direct); Common Stock — 20,424 shares (Indirect, Trust)

Footnotes (1)

Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. This transaction was executed in multiple trades in prices ranging from $39.6016 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025. Includes 218,188 RSUs. Held by Jonathan Goldsmith Revocable Trust. Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/18/2025 - 04:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSMITH MARK A

(Last)

(First)

(Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/16/2025		S⁽¹⁾		13,496	D	$39.83⁽²⁾	428,720⁽³⁾⁽⁴⁾	D
Common Stock								20,424	I	Trust⁽⁵⁾
Common Stock								20,424	I	Trust⁽⁶⁾
Common Stock								465,604	I	Trust⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. This transaction was executed in multiple trades in prices ranging from $39.6016 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.

4. Includes 218,188 RSUs.

5. Held by Jonathan Goldsmith Revocable Trust.

6. Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.

7. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Remarks:

President and Chief Executive Officer

	/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many RVMD shares did CEO Mark Goldsmith sell on June 16, 2025?

CEO Mark Goldsmith sold 13,496 shares of RVMD common stock on June 16, 2025 at a weighted average price of $39.83 per share. This transaction was executed pursuant to a Rule 10b5-1 trading plan established on May 31, 2023.

What is the purpose of RVMD CEO Mark Goldsmith's stock sale in June 2025?

The stock sale was made to satisfy the CEO's tax withholding obligation upon the vesting of restricted stock units (RSUs). The transaction was executed according to a pre-established Rule 10b5-1 instruction letter adopted on May 31, 2023.

How many RVMD shares does Mark Goldsmith own after the June 2025 transaction?

After the transaction, Mark Goldsmith beneficially owns: 428,720 shares directly (including 218,188 RSUs and 652 ESPP shares), plus indirect ownership through trusts of: 20,424 shares in the Jonathan Goldsmith Revocable Trust, 20,424 shares in the Rebecca Eve Goldsmith Trust, and 465,604 shares in the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

What was the selling price range for RVMD CEO's stock sale on June 16, 2025?

The shares were sold in multiple trades at prices ranging from $39.6016 to $39.8291 per share, with a weighted average sale price of $39.83.